Stock listing
NASDAQ:PMVP PMV Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of PMV Pharmaceuticals, Inc.
Follow PMV Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PMVP
$0.876 USD -0.434 (-33.1%)
Close on Nov 20, 2026
- Day range
- $0.660 – $1.340 USDNov 20, 2026
- Volume
- 4.81M sharesNov 20, 2026
- Market cap
- $66.17M USDAt the close on Nov 20, 2026 · price × 75.53M shares outstanding
- 52-week range
- $0.660 – $1.910 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.06M USDMedian day 468,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PMVP · Home | $0.876 USD | -0.434 (-33.1%) | 4,813,400 | $1.340 | $1.340 | $0.660 | $1.310 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PMVP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.876 | -0.434 | -33.1% | $1.340 | $1.340 | $0.660 | 4,813,400 | |
| $1.310 | +0.090 | +7.4% | $1.240 | $1.330 | $1.230 | 1,191,000 | |
| $1.220 | 0.000 | 0.0% | $1.210 | $1.280 | $1.190 | 430,800 | |
| $1.220 | +0.030 | +2.5% | $1.220 | $1.230 | $1.070 | 713,400 | |
| $1.190 | -0.080 | -6.3% | $1.270 | $1.300 | $1.180 | 585,600 | |
| $1.270 | +0.060 | +5.0% | $1.220 | $1.270 | $1.190 | 290,800 | |
| $1.210 | -0.050 | -4.0% | $1.250 | $1.269 | $1.180 | 353,400 | |
| $1.260 | +0.040 | +3.3% | $1.230 | $1.270 | $1.230 | 154,100 | |
| $1.220 | -0.030 | -2.4% | $1.230 | $1.260 | $1.175 | 584,800 | |
| $1.250 | -0.010 | -0.8% | $1.270 | $1.310 | $1.240 | 189,400 | |
| $1.260 | -0.015 | -1.2% | $1.280 | $1.290 | $1.240 | 194,300 | |
| $1.275 | -0.050 | -3.8% | $1.300 | $1.300 | $1.200 | 475,600 | |
| $1.325 | -0.055 | -4.0% | $1.400 | $1.440 | $1.305 | 529,800 | |
| $1.380 | +0.010 | +0.7% | $1.370 | $1.420 | $1.330 | 458,200 | |
| $1.370 | +0.060 | +4.6% | $1.310 | $1.400 | $1.310 | 440,400 | |
| $1.310 | -0.040 | -3.0% | $1.330 | $1.331 | $1.210 | 1,212,800 | |
| $1.350 | -0.030 | -2.2% | $1.390 | $1.390 | $1.330 | 238,100 | |
| $1.380 | +0.130 | +10.4% | $1.250 | $1.390 | $1.220 | 348,900 | |
| $1.250 | +0.120 | +10.6% | $1.170 | $1.280 | $1.155 | 375,169 | |
| $1.130 | -0.140 | -11.0% | $1.260 | $1.285 | $1.100 | 648,579 | |
| $1.270 | -0.035 | -2.7% | $1.300 | $1.330 | $1.255 | 171,000 | |
| $1.305 | -0.055 | -4.0% | $1.360 | $1.370 | $1.300 | 128,600 | |
| $1.360 | -0.030 | -2.2% | $1.370 | $1.410 | $1.350 | 236,600 | |
| $1.390 | +0.135 | +10.8% | $1.260 | $1.410 | $1.260 | 347,600 | |
| $1.255 | +0.045 | +3.7% | $1.210 | $1.290 | $1.210 | 196,000 | |
| $1.210 | -0.080 | -6.2% | $1.280 | $1.300 | $1.200 | 357,600 | |
| $1.290 | +0.050 | +4.0% | $1.260 | $1.330 | $1.240 | 376,600 | |
| $1.240 | -0.110 | -8.1% | $1.330 | $1.370 | $1.230 | 525,800 | |
| $1.350 | -0.060 | -4.3% | $1.400 | $1.466 | $1.315 | 541,300 | |
| $1.410 | -0.110 | -7.2% | $1.550 | $1.550 | $1.400 | 398,600 | |
| $1.520 | +0.030 | +2.0% | $1.490 | $1.610 | $1.480 | 891,700 | |
| $1.490 | -0.010 | -0.7% | $1.510 | $1.540 | $1.460 | 461,400 | |
| $1.500 | -0.110 | -6.8% | $1.590 | $1.600 | $1.480 | 607,400 | |
| $1.610 | -0.170 | -9.6% | $1.780 | $1.810 | $1.591 | 616,100 | |
| $1.780 | -0.010 | -0.6% | $1.800 | $1.840 | $1.700 | 1,185,500 | |
| $1.790 | +0.040 | +2.3% | $1.750 | $1.870 | $1.680 | 3,735,800 | |
| $1.750 | +0.080 | +4.8% | $1.680 | $1.910 | $1.630 | 1,647,200 | |
| $1.670 | +0.240 | +16.8% | $1.440 | $1.725 | $1.440 | 3,124,700 | |
| $1.430 | +0.070 | +5.1% | $1.370 | $1.450 | $1.360 | 550,900 | |
| $1.360 | +0.030 | +2.3% | $1.340 | $1.390 | $1.300 | 336,100 | |
| $1.330 | -0.005 | -0.4% | $1.320 | $1.380 | $1.290 | 271,200 | |
| $1.335 | -0.035 | -2.6% | $1.360 | $1.400 | $1.280 | 486,300 | |
| $1.370 | -0.140 | -9.3% | $1.510 | $1.520 | $1.365 | 570,700 | |
| $1.510 | +0.035 | +2.4% | $1.470 | $1.525 | $1.460 | 316,900 | |
| $1.475 | -0.025 | -1.7% | $1.500 | $1.510 | $1.445 | 330,000 | |
| $1.500 | +0.040 | +2.7% | $1.460 | $1.520 | $1.430 | 1,184,900 | |
| $1.460 | +0.030 | +2.1% | $1.430 | $1.500 | $1.420 | 430,800 | |
| $1.430 | +0.070 | +5.1% | $1.370 | $1.510 | $1.370 | 1,021,700 | |
| $1.360 | -0.100 | -6.8% | $1.450 | $1.450 | $1.350 | 705,400 | |
| $1.460 | +0.060 | +4.3% | $1.420 | $1.495 | $1.380 | 1,109,800 | |
| $1.400 | -0.040 | -2.8% | $1.450 | $1.505 | $1.400 | 538,600 | |
| $1.440 | +0.065 | +4.7% | $1.340 | $1.450 | $1.340 | 673,600 | |
| $1.375 | +0.035 | +2.6% | $1.340 | $1.390 | $1.340 | 419,100 | |
| $1.340 | +0.050 | +3.9% | $1.310 | $1.375 | $1.290 | 1,163,500 | |
| $1.290 | +0.050 | +4.0% | $1.240 | $1.350 | $1.240 | 530,000 | |
| $1.240 | -0.020 | -1.6% | $1.260 | $1.289 | $1.199 | 576,300 | |
| $1.260 | -0.030 | -2.3% | $1.260 | $1.290 | $1.242 | 704,300 | |
| $1.290 | +0.080 | +6.6% | $1.150 | $1.310 | $1.115 | 6,823,800 | |
| $1.210 | -0.010 | -0.8% | $1.240 | $1.240 | $1.210 | 1,115,500 | |
| $1.220 | -0.020 | -1.6% | $1.250 | $1.250 | $1.215 | 90,900 | |
| $1.240 | -0.070 | -5.3% | $1.300 | $1.310 | $1.220 | 197,500 | |
| $1.310 | +0.005 | +0.4% | $1.300 | $1.320 | $1.295 | 94,500 | |
| $1.305 | 0.000 | 0.0% | $1.310 | $1.320 | $1.290 | 211,700 | |
| $1.305 | -0.025 | -1.9% | $1.340 | $1.360 | $1.300 | 168,300 | |
| $1.330 | +0.030 | +2.3% | $1.320 | $1.340 | $1.300 | 131,300 | |
| $1.300 | +0.020 | +1.6% | $1.290 | $1.350 | $1.270 | 458,100 |
- Ticker
- NASDAQ:PMVP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
Nov 20, 2026
Closed $0.876 (-33.1%) on Nov 20, 2026
PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
Nov 10, 2026
Closed $1.22 (-2.4%) on Nov 10, 2026
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
Nov 4, 2026
Closed $1.33 (-4.0%) on Nov 4, 2026
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Oct 5, 2026
Closed $1.78 (-0.6%) on Oct 5, 2026
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
Sep 8, 2026
Closed $1.34 (+3.9%) on Sep 8, 2026
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
Aug 31, 2026
Closed $1.29 (+6.6%) on Sep 1, 2026
PMV Pharma Announces Proposed Public Offering of Securities
Aug 31, 2026
Closed $1.29 (+6.6%) on Sep 1, 2026
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Aug 31, 2026
Closed $1.29 (+6.6%) on Sep 1, 2026
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Aug 14, 2026
Closed $1.26 (+3.7%) on Aug 14, 2026
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
May 12, 2026
Closed $1.42 (+2.2%) on May 12, 2026
PMV Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 57 in all · newest Nov 20, 2026 · oldest 2020
- Decks
- 5 decks · latest September 2026
Where PMV Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PMVP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PMVP | BOATS | United States | USD |
Valuation
Price/book 1.2× against a median of 3.0×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$36.25M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.43
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.36M | US$55.53M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.56M | US$44.51M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Atara Biotherapeutics, Inc. · NASDAQ:ATRA | US$64.49M | US$64.14M | n/a | 16.2× | n/a | n/a | −368.6% | n/a | 1.43 |
| Median of the others | US$66.45M | US$51.12M | 16.2× | 3.0× | −159.5% | 0.0× | 1.43 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.35 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| David H. Mack | Co-Founder, President & CEO |
| Philip Herman | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Laurie Stelzer | Chair, Board of Directors |
| Charles M Baum | Director |
| David H. Mack | Co-Founder, President & CEO |
| Matt Eckler | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −2.4% |
| Q2 2026 | Aug 14, 2026 · Before open | +3.7% |
| Q1 2026 | May 12, 2026 · Before open | +2.2% |
| Q4 2025 | Mar 5, 2026 | +9.3% |
| Q3 2025 | Nov 12, 2025 · Before open | +6.8% |
| Q2 2025 | Aug 7, 2025 · Before open | −4.6% |
| Q1 2025 | May 9, 2025 · Before open | −0.1% |
| Q4 2024 | Feb 26, 2025 · After close | −1.4% |
| Q3 2024 | Nov 7, 2024 · Before open | +7.2% |
| Q2 2024 | Aug 8, 2024 · Before open | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −2.8% |
| Q4 2023 | Feb 29, 2024 · After close | +1.4% |
| Q3 2023 | Nov 9, 2023 · Before open | +2.1% |
| Q2 2023 | Aug 9, 2023 · Before open | +27.7% |
| Q1 2023 | May 10, 2023 · Before open | +8.3% |
| Q4 2022 | Mar 1, 2023 · Before open | −14.2% |
| Q3 2022 | Nov 8, 2022 · Before open | +1.1% |
| Q2 2022 | Aug 9, 2022 · Before open | −8.1% |
| Q1 2022 | May 10, 2022 · Before open | +9.7% |
| Q4 2021 | Mar 1, 2022 · Before open | +5.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 27 slides | September 2026 |
| Investor Presentation (September 2025) | Investor deck | 43 slides | Sep 10, 2025 |
| Technical Presentation (October 2023) | Technical | 25 slides | Oct 12, 2023 |
| ASCO 2022 PC14586 Investor Event | Conference | 32 slides | Jun 8, 2022 |
| ASCO 2022 | Conference | 16 slides | June 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants Announced: about US$50.8M · US$1.21 a share · 1 warrant at US$1.21 for 60 months · TD Cowen Dealers: TD Cowen (lead) | Sep 1, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Sep 24, 2020.
- Price
- US$18.00 a share
- Shares offered
- 11,765,000 shares of common stock
- Offering size
- US$211.8 million
- Underwriters' option
- Up to 1,764,750 more shares
- Underwriters
- Goldman Sachs & Co. LLC, BofA Securities, Cowen, Evercore ISI · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 26, 2020 |
| Filed publicly | Sep 4, 2020 |
| Amended twice | Newest Sep 24, 2020 |
| Shares registered with an exchange | Sep 21, 2020 |
| Declared effective by the SEC | Sep 24, 2020 |
| Final prospectus, with the price | Sep 25, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 25, 2020 |
| EFFECT · Notice that a registration is effective | Sep 24, 2020 |
| CERT · Exchange's certificate of listing | Sep 24, 2020 |
| S-1/A · Registration statement, amended | Sep 24, 2020 |
| CORRESP · Letter to the SEC | Sep 22, 2020 |
| CORRESP · Letter to the SEC | Sep 22, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 21, 2020 |
| CORRESP · Letter to the SEC | Sep 21, 2020 |
| S-1/A · Registration statement, amended | Sep 21, 2020 |
| UPLOAD · Letter from the SEC | Sep 17, 2020 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 11, 2020 |
| CORRESP · Letter to the SEC | Sep 4, 2020 |
| S-1 · Registration statement | Sep 4, 2020 |
| UPLOAD · Letter from the SEC | Aug 18, 2020 |
| DRS/A · Draft registration statement, amended | Aug 3, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jul 31, 2020 |
| UPLOAD · Letter from the SEC | Jul 23, 2020 |
| DRS · Draft registration statement | Jun 26, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 25, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 133.0K | 1.14M | 1.26M | 650.0K | 1.28M | 318.0K | 388.0K | 338.0K |
| Gross profit | -133.0K | -1.14M | -1.26M | -650.0K | -1.28M | -318.0K | -388.0K | -338.0K |
| Research and development | 69.9M | 58.5M | 55.9M | 52.0M | 36.5M | 23.9M | 20.8M | 13.9M |
| Selling, general and administrative | 16.3M | 26.9M | 24.2M | 25.1M | 21.8M | 11.0M | 5.88M | 5.04M |
| Operating income | -86.2M | -85.4M | -80.1M | -77.0M | -58.3M | -34.9M | -26.6M | -18.9M |
| Depreciation and amortization | 133.0K | 1.14M | 1.26M | 315.0K | 307.0K | 318.0K | 388.0K | 338.0K |
| EBITDA | -86.1M | -84.3M | -78.9M | -76.7M | -58.0M | -34.6M | -26.2M | -18.6M |
| Interest expense | 4.03M | 777.0K | 826.0K | 1.29M | 0 | |||
| Income before tax | -79.9M | -74.8M | -69.0M | -73.3M | -57.8M | -34.4M | -25.3M | -17.5M |
| Income tax | -2.17M | -16.1M | 2.00K | -9.00K | 23.0K | 6.00K | 8.00K | 3.00K |
| Net income | -77.7M | -58.7M | -69.0M | -73.3M | -57.8M | -34.4M | -25.4M | -17.5M |
| Earnings per share, basic | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | -8.35 | -5.82 |
| Earnings per share, diluted | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | -8.35 | -5.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 38.0M | 40.9M | 37.7M | 108.3M | 172.5M | 361.4M | 73.3M | 30.3M |
| Short-term investments | 75.0M | 128.6M | 165.4M | 132.8M | 124.7M | 0 | 28.2M | 31.6M |
| Current assets | 115.2M | 175.7M | 207.4M | 247.0M | 301.3M | 364.8M | 102.1M | 62.2M |
| Property, plant and equipment | 237.0K | 409.0K | 10.7M | 11.0M | 3.09M | 569.0K | 739.0K | 1.02M |
| Total assets | 116.6M | 191.3M | 252.2M | 270.3M | 331.6M | 365.5M | 103.0M | 63.5M |
| Accounts payable | 3.15M | 6.58M | 3.24M | 3.00M | 3.19M | 1.61M | 2.84M | 1.04M |
| Current liabilities | 11.4M | 14.4M | 14.0M | 10.8M | 12.2M | 6.41M | 4.52M | 2.33M |
| Total debt | 838.0K | 1.19M | 13.3M | 14.0M | 11.2M | 168.9M | 107.2M | |
| Total liabilities | 11.8M | 15.2M | 26.5M | 24.3M | 23.0M | 6.41M | 4.57M | 109.6M |
| Shareholders' equity | 104.7M | 176.1M | 225.7M | 246.0M | 308.6M | 359.1M | -70.5M | -46.1M |
| Shares outstanding | 53.3M | 51.9M | 51.4M | 45.8M | 45.4M | 44.8M | 3.05M | 45.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -73.6M | -51.3M | -55.7M | -63.8M | -46.6M | -32.7M | -22.1M | -15.2M |
| Capital spending | -29.0K | -655.0K | -962.0K | -7.98M | -1.35M | -148.0K | -109.0K | -452.0K |
| Free cash flow | -73.6M | -51.9M | -56.6M | -71.7M | -47.9M | -32.9M | -22.2M | -15.6M |
| Cash from investing | 70.2M | 53.4M | -50.5M | -1.37M | -143.6M | 27.9M | 3.23M | 21.7M |
| Cash from financing | 505.0K | 313.0K | 35.6M | 958.0K | 2.02M | 293.0M | 61.8M | 61.8M |
| Share buybacks | 958.0K | 2.02M | 293.0M | |||||
| Change in cash | -2.89M | 2.35M | -70.6M | -64.2M | -188.1M | 288.1M | 43.0M | 6.51M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 5, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 1, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 1, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 31, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2026 | Results | SEC |
| 10-K · Annual report | Mar 6, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 27, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 23, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 28, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 12, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 29, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 27, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 25, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 20, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| SC TO-I/A | Aug 14, 2024 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| SC TO-I | Jul 16, 2024 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 9, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 24, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 18, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 24, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 22, 2023 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Oct 12, 2023 | Current report | SEC |
| 8-K · Current report | Oct 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 23, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 7, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2023 | Meeting outcome | SEC |
| SC 13G · Big-stake notice | May 19, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | May 10, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2023 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2023 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| POS AM · Amendment to an effective registration | Mar 1, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 1, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 1, 2023 | Results | SEC |
| POSASR | Mar 1, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 24, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 24, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 8, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2022 | Results | SEC |
| 8-K · Current report | Nov 4, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Sep 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2022 | Results | SEC |
| SC 13G · Big-stake notice | Jul 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 7, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 17, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jun 8, 2022 | Current report | SEC |
| 4 · Change in ownership | Jun 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2022 | Insider trade | SEC |
This page holds 200 of 394 filings. Open Filings
Cap table
Built by 6ix from PMV Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 75,534,742
- Fully diluted
- 75,534,742
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 75,534,742 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 75,534,742 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carol G. Gallagher Other companies: TRex Bio, Inc. (Lead Independent Director · Since at least Nov 5, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past); Tempest Therapeutics, Inc. (Director · Jun 20, 2019 – Jun 22, 2020 · Past) | Director · Since at least Nov 3, 2022 |
| Richard Heyman Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); ORIC Pharmaceuticals, Inc. (Chairman · Since at least Apr 23, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past) | Director · Since at least Sep 24, 2020 |
| Arnold L Oronsky Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 1, 2020 · Past); MacroGenics, Inc. (Director · Oct 9, 2013 – Feb 18, 2014 · Past); Tesaro Inc (Director · Jun 27, 2012 – Aug 7, 2018 · Past); Anesiva Inc (Director · Jun 22, 2006 – May 9, 2008 · Past); Myogen Inc (Director · May 4, 2006 – Nov 13, 2006 · Past); Dynavax Technologies Corporation (Director · Feb 23, 2006 – May 28, 2020 · Past) | Director · Sep 24, 2020 – Sep 25, 2020 · Past |
| Charles Baum Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Poseida Therapeutics Inc (Director · May 16, 2022 – Jan 8, 2025 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Immunomedics Inc (Director · Feb 23, 2019 – Oct 23, 2020 · Past) | Director · Since at least Apr 1, 2021 |
| Laurie Stelzer Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Spyre Therapeutics, Inc. (Chair of the Audit Committee · Since at least Nov 22, 2023); Surface Oncology Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past) | Chair, Board of Directors · Since at least Jun 2, 2022 |
| Thilo Schroeder Other companies: ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Dec 8, 2020 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Dec 5, 2024 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – May 22, 2019 · Past) | Director · Sep 24, 2020 – Oct 6, 2021 · Past |
| Winston Kung Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); ArriVent BioPharma, Inc. (Chief Financial Officer · Since at least Jan 25, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022) | COO, CFO · Sep 24, 2020 – May 12, 2023 · Past |
| David H. Mack Other companies: Aduro Biotech Inc (Director · Feb 19, 2019 – May 5, 2020 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – Oct 25, 2013 · Past) | Co-Founder, President & CEO · Since at least Sep 24, 2020 |
| Arnold J Levine Other companies: MeiraGTx Holdings plc (Director · Jun 19, 2019 – Jun 7, 2022 · Past) | Director · Since at least Sep 24, 2020 |
| Kirsten Flowers Other companies: Kura Oncology, Inc. (CCO & Chief Strategy Officer · Jan 6, 2020 – Jan 27, 2023 · Past) | Director · Since at least Jan 5, 2022 |
All 16 people
| Person | Seat |
|---|---|
| Robert Ticktin Other companies: EPIRUS Biopharmaceuticals Inc (General Counsel · Jul 15, 2014 – May 27, 2016 · Past) | General Counsel & COO · Since at least Apr 21, 2025 |
| Matt Eckler | Director · Since Oct 5, 2026 · Appointed, no departure found |
| Matt Eckler | Director · Since at least Oct 5, 2026 |
| Michael Carulli | Chief Financial Officer · Since at least Jan 5, 2024 |
| Philip Herman | Chief Commercial Officer · Since Sep 8, 2026 · Appointed, no departure found |
| Philip Herman | Chief Commercial Officer · Since at least Sep 8, 2026 |
Log in to ask 6ix AI your own questions about PMV Pharmaceuticals, Inc.